These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37337059)

  • 21. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
    Wen P; Chen SD; Wang JR; Zeng YH
    Oncol Res; 2019 May; 27(5):583-592. PubMed ID: 31053181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small-size (40 µm) Beads Loaded with Irinotecan in the Treatment of Patients with Colorectal Liver Metastases.
    Mauri G; Rossi D; Frassoni S; Bonomo G; Camisassi N; Della Vigna P; Bagnardi V; Maiettini D; Varano GM; Zampino MG; Orsi F
    Cardiovasc Intervent Radiol; 2022 Jun; 45(6):770-779. PubMed ID: 35029709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An investigation of efficacy, safety, and prognostic factors of drug-eluting beads-transarterial chemoembolization operation with CalliSpheres
    Zhang X; Lin X; Qiu H; Peng Z
    J Clin Lab Anal; 2019 Oct; 33(8):e22975. PubMed ID: 31328832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation.
    Vogl TJ; Lahrsow M; Albrecht MH; Hammerstingl R; Thompson ZM; Gruber-Rouh T
    Eur J Radiol; 2018 May; 102():138-145. PubMed ID: 29685527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does Bead Size Affect Patient Outcome in Irinotecan-Loaded Beads Chemoembolization Plus Systemic Chemotherapy Regimens for Liver-Dominant Colorectal Cancer? Results of an Observational Study.
    Boeken T; Moussa N; Pernot S; Abed A; Dean C; Taieb J; Sapoval M; Pellerin O
    Cardiovasc Intervent Radiol; 2020 Jun; 43(6):866-874. PubMed ID: 32103303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Value of TACE With Irinotecan-loaded Drug-eluting Beads (DEBIRI) in Patients With Liver Metastases from Unresectable Colorectal Cancer.
    Ishikawa T; Imai M; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
    Anticancer Res; 2023 Aug; 43(8):3647-3651. PubMed ID: 37500124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transarterial Chemoembolization (TACE) Using Mitomycin with or without Irinotecan for Hepatocellular Carcinoma in European Patients.
    Gruber-Rouh T; Kamal A; Eichler K; Naguib NN; Beeres M; Langenbach M; Vogl TJ
    Oncol Res Treat; 2018; 41(7-8):438-442. PubMed ID: 30007958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response rate and safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40-µm doxorubicin-eluting microspheres.
    Albrecht KC; Aschenbach R; Diamantis I; Eckardt N; Teichgräber U
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):23-32. PubMed ID: 32880029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
    Liu X; Ou K; Ma X; Gao L; Wang Q; Zhang H; Yang L
    BMC Cancer; 2022 Jul; 22(1):807. PubMed ID: 35864467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety.
    Li H; Wu F; Duan M; Zhang G
    Medicine (Baltimore); 2019 May; 98(21):e15314. PubMed ID: 31124925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.
    Orlacchio A; Chegai F; Roma S; Merolla S; Bosa A; Francioso S
    Radiol Med; 2020 Jan; 125(1):98-106. PubMed ID: 31583558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study.
    Vogl TJ; Gruber T; Balzer JO; Eichler K; Hammerstingl R; Zangos S
    Radiology; 2009 Jan; 250(1):281-9. PubMed ID: 19092099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study.
    Bower M; Metzger T; Robbins K; Tomalty D; Válek V; Boudný J; Andrasina T; Tatum C; Martin RC
    HPB (Oxford); 2010 Feb; 12(1):31-6. PubMed ID: 20495642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
    Zhang ZS; Li HZ; Ma C; Xiao YD
    BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of drug-eluting microspheres chemoembolization under cone beam computed tomography control in patients with early and intermediate stage hepatocellular carcinoma.
    Korsic S; Levasic N; Dezman R; Zupan LAL; Trotovsek B; Jansa R; Smid A; Popovic P
    Radiol Oncol; 2022 Aug; 56(3):311-318. PubMed ID: 35535426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early Experience with 70-150 μm Irinotecan Drug-eluting Beads (M1-DEBIRI) for the Treatment of Unresectable Hepatic Colorectal Metastases.
    Akinwande O; Scoggins C; Martin RC
    Anticancer Res; 2016 Jul; 36(7):3413-8. PubMed ID: 27354601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Tolerability of Topotecan-Eluting Radiopaque Microspheres for Hepatic Chemoembolization in a Rabbit Preclinical Model.
    Mikhail AS; Levy EB; Krishnasamy VP; Woods DL; Esparza-Trujillo JA; Bakhutashvili I; Banovac F; Wakim PG; Negussie AH; Tang Y; Henman A; Willis SL; Karanian JW; Pritchard WF; Lewis AL; Wood BJ
    Cardiovasc Intervent Radiol; 2020 Dec; 43(12):1918-1924. PubMed ID: 32803282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
    Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
    AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
    [No Abstract]   [Full Text] [Related]  

  • 39. LifePearl microspheres loaded with irinotecan in the treatment of Liver-dominant metastatic colorectal carcinoma: feasibility, safety and pharmacokinetic study.
    Maleux G; Prenen H; Helmberger T; Spriet I; Isailovic TV; Pereira P
    Anticancer Drugs; 2020 Nov; 31(10):1084-1090. PubMed ID: 32932279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-Eluting Microsphere Versus Cisplatin-Based Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma: Propensity Score-Matched Analysis.
    Chu HH; Gwon DI; Kim JH; Ko GY; Shin JH; Yoon HK
    AJR Am J Roentgenol; 2020 Sep; 215(3):745-752. PubMed ID: 32569514
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.